|
![]() | 2013/4 |
![]() | Department of Pharmacy & Pharmacology |
![]() | 3 |
![]() | Intermediate (FHEQ level 5) |
![]() |
Semester 1 |
![]() | EX 100% |
![]() |
Like-for-like reassessment (where allowed by programme regulations) |
![]() | Before taking this unit you must take PA10014 |
![]() | Aims: To provide students with an understanding of decision making in health care, including the assessment and interpretation of risk, benefit-risk considerations, and health care planning both at a population level and at the level of individual patients. Learning Outcomes: After completing this unit, students should be able to: * Demonstrate and apply knowledge of how benefits and risks of medicine use are assessed, both at the level of individual patients and at the level of populations. * Critically appraise and interpret publications regarding pre and post-marketing evaluations of risks and benefits of medicines. * Identify patient and prescription problems and propose suitable solutions. Skills: Analytical skills, critical thinking, risk assessment and decision making. All these skills are taught, facilitated and assessed. Content: Spontaneous reporting and pharmacoepidemiology: introduction to the principles and methods of signal generation and evaluation in postmarketing safety assessment of medicines. Critical appraisal: introduction to critical appraisal of randomised controlled clinical trials, case control studies, cohort studies and pharmacoeconomics analyses. Clinical pharmacy: introduction to clinical pharmacy, risk assessment in health care planning, drug- and disease monitoring, and medication errors. Pharmacoeconomics: introduction to the principles of health economics. Throughout this module, the students will use a range of aspects from these four areas and apply them to different scenarios in clinical practice. |
![]() |
PA20298 is a Designated Essential Unit on the following programmes:Department of Pharmacy & Pharmacology
|